Clostridium difficile infection causes severe diarrhoea in hospital patients when normal gut flora is disrupted by broad-spectrum antibiotics. In the USA alone there are 453,000 cases resulting in 29,300 deaths per year, with one in nine patients over 65 with C. difficile dying within 30 days of diagnosis (CDC). There is no vaccine currently available. The global therapeutics and prophylactics market for C. difficile infections is forecast to increase to over $1.5 billion by 2024 (GlobalData). Prokarium has recently developed a thermostable formulation, which would help its C. difficile vaccine to capture certain markets, such as nursing homes and patients on elective surgery. Prokarium is also modifying its vaccine candidate which previously gave 75% protection in a murine model to further improve efficacy before taking it to clinic.